Viewing Study NCT03051256

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:19 PM
Ignite Modification Date: 2026-02-23 @ 8:09 PM
Study NCT ID: NCT03051256
Status: COMPLETED
Last Update Posted: 2023-11-01
First Post: 2017-02-03
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
Sponsor: Relmada Therapeutics, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Depressive Disorder, Major View
None Depressive Disorder, Treatment-Resistant View
Keywords:

Keywords

Keyword Brief Keyword Text View
None REL-1017 View
None d-Methadone View
None Methadone View
None Depression View
None Refractory Depression View
None Antidepressant View
None Adjunctive Treatment View
None NMDA Receptor Antagonist View
None Excitatory Amino Acid Antagonist View
None Glutamate Antagonist View